- $1.03bn
- $931.91m
- $599.40m
- 80
- 45
- 79
- 76
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 228 | 245 | 380 | 539 | 599 |
Cost of Revenue | |||||
Gross Profit | 212 | 224 | 351 | 499 | 545 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 200 | 243 | 419 | 558 | 596 |
Operating Profit | 28.4 | 1.9 | -39 | -19 | 3.6 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 27.9 | 0.9 | -37.7 | -20 | 6.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 27.9 | 5.3 | -42.5 | -10.2 | -11.8 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 24.2 | 5.3 | -42.5 | -10.2 | -11.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 24.2 | 5.3 | -42.5 | -10.2 | -11.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.431 | 0.082 | -0.629 | -0.086 | -0.095 |
Dividends per Share |